Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?

Affiliations

¹ Department of Cardiovascular and Pulmonary Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli, 8, Rome 00168, Italy.
² Department of Pharmacology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli, 8, Rome 00168, Italy.

Comment

Giovanna Liuzzo et al. Eur Heart J. 2021.

. 2021 Nov 14;42(43):4418-4419.

doi: 10.1093/eurheartj/ehab673.

¹ Department of Cardiovascular and Pulmonary Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli, 8, Rome 00168, Italy.
² Department of Pharmacology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli, 8, Rome 00168, Italy.

No abstract available

Comment on

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Valgimigli M, et al. N Engl J Med. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449185 Clinical Trial.